BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream.

TScan Therapeutics recognizes its co-founders, Lea Hachigian Ph.D. and Tomasz Kula Ph.D., who were honored as healthcare pioneers in the Forbes 30 Under 30 list Class of 2020.

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the submission of its Biologics License Application (BLA) for Vicinium for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) under Rolling Review to the U.S. Food and Drug Administration (FDA).

Trials Conducted Internationally by Marrone Bio and its Wholly Owned Subsidiary, Pro Farm Technologies OY

2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm

This ready-to-use rescue treatment can be used when and where a seizure cluster occurs thanks to Aptar’s proven, intuitive and convenient Unidose Liquid System.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented Phase 1 data yesterday from the healthy volunteer study of ALPN-101,

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Glioblastoma Drug Development Annual Summit

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented data on the cost effectiveness of Doptelet® for the treatment of thrombocytopenia in patients with chronic liver diseases who are scheduled to undergo a procedure at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag for the treatment of immune thrombocytopenia, at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.